

INCIDENCE OF POST-OPERATIVE NAUSEA AND VOMITING IN LAPAROSCOPIC CHOLECYSTECTOMY WITH A SINGLE DOSE OF PREOPERATIVE DEXAMETHASONE

NAEEMI MF

Department of Surgery, Surgical Unit-3 Allied Hospital, Faisalabad, Pakistan

*Correspondence author email address: faisalnaeemi499@gmail.com

(Received, 27th June 2023, Revised 20th September 2023, Published 27th October 2023)

Abstract: *Laparoscopic cholecystectomy is a commonly performed surgical procedure that frequently results in post-operative nausea and vomiting (PONV). Dexamethasone, a synthetic glucocorticoid with potent anti-inflammatory, immune-modulating, analgesic, and anti-emetic effects, effectively reduces the incidence of PONV after laparoscopic cholecystectomy. In this double-blind, placebo-controlled study, we aimed to investigate the efficacy of a single 8 mg dose of dexamethasone in preventing PONV in patients undergoing laparoscopic cholecystectomy. Sixty patients were randomized into two groups: group A, who received an 8 mg dexamethasone injection in a 2-ml preparation, and group B, who received normal saline during induction. Both groups received standardized anesthesia. Post-operatively, the incidence of nausea and vomiting was observed in both groups. Our study's findings indicate that no substantial variances were observed between the two cohorts in terms of medical or demographic factors. However, a lower proportion of patients in group A exhibited post-operative nausea and vomiting (PONV), while group B had a higher demand for anti-emetic medications to alleviate PONV symptoms. Thus, we can infer that administering a solitary dose of dexamethasone before laparoscopic cholecystectomy can reduce the risk of post-operative complications in patients.*

Keywords: Cholelithiasis; laparoscopic cholecystectomy; dexamethasone; post-operative nausea and vomiting.

Introduction

Laparoscopic cholecystectomy, a minimally invasive procedure for gallbladder removal, has become the preferred approach due to its advantages in reducing post-operative pain, recovery time, and hospital stay compared to traditional open surgery (Agarwal et al., 2015). However, one common challenge associated with laparoscopic cholecystectomy is the occurrence of post-operative nausea and vomiting (PONV). PONV can be distressing for patients and may lead to complications, including wound dehiscence, dehydration, and delayed discharge (Sweis et al., 2013). Anti-emetic medications have been a mainstay in preventing PONV, with various drugs and regimens employed to mitigate these symptoms (Gan et al., 2020). Among the pharmacological interventions, dexamethasone, a potent glucocorticoid, has shown promise as an effective prophylactic agent against PONV (Gan et al., 2020). Dexamethasone's anti-inflammatory and anti-emetic properties make it a potential candidate for reducing the incidence of PONV in patients undergoing laparoscopic cholecystectomy. Several studies have explored its use in preventing PONV with favorable outcomes. However, dexamethasone administration's optimal dosage and timing remain subjects of ongoing investigation (Khalaj et al., 2013).

This study aims to contribute to the body of evidence by assessing the incidence of post-operative nausea and vomiting in patients undergoing laparoscopic cholecystectomy after receiving a single preoperative dose of dexamethasone. Understanding the potential benefits and risks associated with dexamethasone administration in this context is crucial for optimizing patient outcomes and reducing the burden of PONV following this common surgical procedure. We seek to provide valuable insights for

clinical practice and patient care by addressing this research question.

Methodology

After obtaining approval from the hospital ethics committee and informed consent, 60 patients were computer-randomized for a double-blind placebo-controlled study. The patients studied were ASA I or II, aged 20 to 60 yr, and underwent general anesthesia for elective laparoscopic cholecystectomy. Patients who had received anti-emetics within 48 hours before surgery or had a history of motion sickness, chronic pain disorder, or pregnancy were excluded. Each patient was randomly allocated to one of the two groups using a computer-generated random number table. Group A received 8 mg dexamethasone in 2-ml preparation 1 minute before anesthesia induction, and Group B received 2-ml normal saline. Study medications were prepared by a single-house surgeon in two identical syringes, who administered the drugs to blind the surgeon and anesthetist.

All the patients received a similar standardized anesthetic regimen. Anesthesia was induced with propofol (2mg/kg i.v) and was maintained with nitrous oxide and isoflurane. Suxamethonium was used to relax the patients before intubation, and neostigmine was used for reversal. The patients were placed in reverse Trendelenburg position with the right side up. The abdomen was insufflated with carbon dioxide with intra-abdominal pressure of 10-16 mm Hg. After surgery, patients were transported to the surgical ward, where they were observed for the 1st, 6th, and 24th hours for any episode of nausea or vomiting or whether the patient required any anti-emetic drug in the post-operative

[Citation: Naeemi, M.F. (2023). Incidence of post-operative nausea and vomiting in laparoscopic cholecystectomy with a single dose of preoperative dexamethasone. *Biol. Clin. Sci. Res. J.*, 2023: 485. doi: <https://doi.org/10.54112/bcsrj.v2023i1.485>]

period. Ondansetron or metoclopramide was used if any episode of vomiting occurred. The Excel software analyses the data and makes the bar and pie charts.

Results

Sixty patients aged 20-60 years were considered, with female preponderance: 88% female and 12% male. Two groups with equal participants were made. Group A constituted all patients with pre-op 8 mg in. dexamethasone in 2-mL preparation at the time of induction, while Group B was made for patients who received 2-mL normal saline. Nausea and vomiting were compared in both groups after the 1st, 6th, and 24th post-operative hours. Also, both groups' demand for anti-emetics was compared in the 24-hour post-operative period. After 1st post-operative hour, nausea was reported in 67% of group B, while only 30% of patients in group 1 experienced nausea. Similarly, 33% of patients from Group 2 and 17% from Group A had an episode of vomiting during 1st post-

operative hour. When compared at the 6th post-operative hour, 37% from group B and 13 % of patients from group A experienced nausea. As a decline in the episodes of nausea and vomiting was observed compared to 1st post-operative hour for nausea, the vomiting pattern followed the same. Only 13 % of patients had an episode of vomiting from group B and just 3 % from group A. After 24 post-operative hours, the two groups' episodes of nausea and vomiting still showed much difference. 13% from Group B and 10% from Group A showed nausea, while just 7% from Group B and 3% of patients from Group A had episodes of vomiting, as shown in Figure 1. In short, after the 1st, 6th, and 24th post-operative hours, both groups experienced nausea and vomiting, but group B was at the upper hand all the time, while small percentages of patients with group A showed these characteristics. The same was observed in terms of post-operative anti-emetic demand. 13% from Group B and 7% patients from Group A were administered anti-emetic doses, keeping its requirement in mind, as shown in Figure 2..




Figure 1 – Comparison of post-operative nausea and vomiting in both groups




Figure 2 – Comparison of 24-hour anti-emetic dose requirement in both groups

Discussion

Laparoscopic surgery has become an accepted and common procedure for patients with cholelithiasis because it has decreased the morbidity associated with open cholecystectomy. However, PONV has been frequently reported in LC. It may be associated with several factors: long periods of carbon dioxide insufflation, biliary duct injury, intraoperative use of sevoflurane/ isoflurane, fentanyl and glycopyrrolate, and female sex (Duems-Noriega and Arino-Blasco, 2015; Odom-Forren, 2022).

In 1981, dexamethasone was first reported as an effective anti-emetic in cancer chemotherapy patients.³ Since then, dexamethasone has been reported to be effective as an anti-emetic in many studies and is equal to or better than other anti-emetic agents, such as ondansetron, metoclopramide, and droperidol (Herrstedt, 2004; Shashidhar, 2010). Recently, it has been reported to be effective in many gynecological and pediatric surgeries (Lerman, 1992). We found that it was also effective for PONV after LC.

The mechanism of the anti-emetic action of dexamethasone is not fully understood. However, it has been suggested that central or peripheral inhibition of secretion or production of serotonin or central inhibition of prostaglandin synthesis may have some role. Dexamethasone also seemed to reduce post-operative pain and length of stay in the hospital compared to placebo (Chu et al., 2014; Hendren et al., 2015; Zhong et al., 2021).

Although we included only a small number of patients in our study, data analysis shows that a single dose of dexamethasone given at the time of induction reduces PONV after LC, which is comparable to other studies done in the past.

It is not an expensive drug, and according to our results and other previous studies, it can be used regularly at the time of induction in LC, and it has been found more effective in preventing PONV than other anti-emetic drugs available (Neufeld, 2009; Shaheed, 2017; Syrous et al., 2021).

The time of administering the drug is quite important because several hours are required for a complete and effective action. So, administering it a few minutes before the surgery starts is considered best (Chou et al., 2016; De Vries et al., 1994).

Surgeons have been reluctant to use glucocorticoid therapy because of possible side effects like delayed wound healing and wound infection. However, these adverse effects related to a single dose of dexamethasone are rare, and no single report related to side effects of a single dose of dexamethasone was found in the literature. In our study, there were no adverse reactions. No delayed wound healing or infections were observed (Kulick et al., 1986; Woodcock et al., 2020). We noticed a reduced incidence of fever in patients who received a single dose of dexamethasone, possibly due to its anti-inflammatory action..

Conclusion

As obvious from this study, administration of a single dose of dexamethasone preoperatively in laparoscopic cholecystectomy patients decreased the incidence of nausea and vomiting and decreased demand for an anti-emetic dose within 24 hours post-operatively. The same can be applied in any setup to decrease post-operative complications of nausea and vomiting, and it can also prove helpful to decrease the burden of post-operative anti-emetics..

Declarations

Data Availability statement

All data generated or analyzed during the study are included in the manuscript.

Ethics approval and consent to participate.

Approved by the department Concerned.

Consent for publication

Approved

Funding

Not applicable

Conflict of interest

The authors declared an absence of conflict of interest.

References

- Agarwal, A. K., Javed, A., Kalayarasan, R., and Sakhuja, P. (2015). Minimally invasive versus the conventional open surgical approach of a radical cholecystectomy for gallbladder cancer: a retrospective comparative study. *HPB* 17, 536-541.
- Chou, R., Gordon, D. B., de Leon-Casasola, O. A., Rosenberg, J. M., Bickler, S., Brennan, T., Carter, T., Cassidy, C. L., Chittenden, E. H., and Degenhardt, E. (2016). Management of Post-operative Pain: a clinical practice guideline from the American pain society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' committee on regional anesthesia, executive committee, and administrative council. *The journal of pain* 17, 131-157.
- Chu, C.-C., Hsing, C.-H., Shieh, J.-P., Chien, C.-C., Ho, C.-M., and Wang, J.-J. (2014). The cellular mechanisms of the anti-emetic action of dexamethasone and related glucocorticoids against vomiting. *European journal of pharmacology* 722, 48-54.
- De Vries, T., Henning, R. H., Hogerzeil, H. V., Fresle, D., Policy, M., and Organization, W. H. (1994). "Guide to good prescribing: a practical manual." World Health Organization.
- Duems-Noriega, O., and Arino-Blasco, S. (2015). Subcutaneous fluid and drug delivery: safe, efficient and inexpensive. *Reviews in Clinical Gerontology* 25, 117-146.
- Gan, T. J., Belani, K. G., Bergese, S., Chung, F., Diemunsch, P., Habib, A. S., Jin, Z., Kovac, A. L., Meyer, T. A., and Urman, R. D. (2020). Fourth consensus guidelines for the management of post-operative nausea and vomiting. *Anesthesia & Analgesia* 131, 411-448.
- Hendren, G., Aponte-Feliciano, A., and Kovac, A. (2015). Safety and efficacy of commonly used anti-emetics. *Expert opinion on drug metabolism & toxicology* 11, 1753-1767.
- Herrstedt, J. (2004). Risk-benefit of anti-emetics in prevention and treatment of chemotherapy-induced nausea and vomiting. *Expert Opinion on Drug Safety* 3, 231-248.
- Khalaj, A. R., Miri, S. R., Porlashkari, M., and Mohammadi, A. (2013). Prophylactic anti-emetic effect of dexamethasone and metoclopramide on the nausea and vomiting induced by laparoscopic cholecystectomy: a randomized, double blind, placebo-controlled trial. *Annals of Bariatric Surgery* 2, 0-0.
- Kulick, M. I., Gordillo, G., Javidi, T., Kilgore Jr, E. S., and Newmeyer III, W. L. (1986). Long-term analysis of patients having surgical treatment for carpal tunnel syndrome. *The Journal of hand surgery* 11, 59-66.
- Lerman, J. (1992). Surgical and patient factors involved in post-operative nausea and vomiting. *British Journal of Anaesthesia* 69, 24S-24S.
- Neufeld, S. M. (2009). Nausea and Vomiting After Posterior Fossa Craniotomy in Children, University of Alberta.
- Odom-Forren, J. (2022). Care of the Thoracic Surgical Patient. *Drain's PeriAnesthesia Nursing-E-Book: A Critical Care Approach*, 396.
- Shaheed, A. Z. (2017). Clinical Practice Guideline for Post-operative Nausea and Vomiting Prevention During Outpatient Surgery.
- Shashidhar, V. K. (2010). A Study Comparing the Efficacy of Ondansetron, Palonosetron and Aprepitant in the Prevention of Chemotherapy induced Nausea and Vomiting in Breast Cancer patients receiving

Moderately Emetogenic Chemotherapy, Cancer Institute (WIA), Chennai.

- Sweis, I., Yegiyants, S. S., and Cohen, M. N. (2013). The management of post-operative nausea and vomiting: current thoughts and protocols. *Aesthetic plastic surgery* 37, 625-633.
- Syrous, N. S., Sundström, T., Søfteland, E., and Jammer, I. (2021). Effects of intraoperative dexmedetomidine infusion on post-operative pain after craniotomy: a narrative review. *Brain Sciences* 11, 1636.
- Woodcock, T., Barker, P., Daniel, S., Fletcher, S., Wass, J., Tomlinson, J., Misra, U., Dattani, M., Arlt, W., and Vercueil, A. (2020). Guidelines for the management of glucocorticoids during the peri-operative period for patients with adrenal insufficiency: guidelines from the Association of Anaesthetists, the Royal College of Physicians and the Society for Endocrinology UK. *Anaesthesia* 75, 654-663.
- Zhong, W., Shahbaz, O., Teskey, G., Beever, A., Kachour, N., Venketaraman, V., and Darmani, N. A. (2021). Mechanisms of nausea and vomiting: current knowledge and recent advances in intracellular emetic signaling systems. *International journal of molecular sciences* 22, 5797.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. © The Author(s) 2023